[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atherosclerotic-cardiovascular-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atherosclerotic-cardiovascular-diseases":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,53,78,103,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100630414","phase-1-tb-500-thymosin-beta-4-17-23-fragment-for-cardiovascular-biomarkers-in-stable-ascvd-100630414",false,"NCT07487363","TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD","A Phase 1\u002F2, Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study of TB-500 (Thymosin Beta 4 17-23 Fragment) in Adults With Stable Atherosclerotic Cardiovascular Disease to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Cardiovascular Biomarkers","TBRIDGE-CV","Inclusion Criteria:\n\n* Age 40-75 years, able to provide written informed consent.\n* Documented stable ASCVD (e.g., prior myocardial infarction \\>6 months ago, prior coronary revascularization, stable angina with objective evidence of ischemia, or symptomatic peripheral artery disease).\n* On stable guideline-directed medical therapy (e.g., statin and antiplatelet therapy unless contraindicated) for at least 8 weeks before screening.\n* Resting systolic blood pressure \\\u003C160 mmHg and diastolic blood pressure \\\u003C100 mmHg (with or without therapy).\n* Able and willing to comply with study visits and procedures.\n\nExclusion Criteria:\n\n* Acute coronary syndrome, stroke\u002Ftransient ischemic attack, or coronary revascularization within 6 months before screening.\n* New York Heart Association (NYHA) class III-IV heart failure or left ventricular ejection fraction \\\u003C35%.\n* Clinically significant arrhythmia requiring recent hospitalization or unstable antiarrhythmic therapy.\n* Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m\\^2) or end-stage renal disease.\n* Clinically significant hepatic impairment (e.g., Child-Pugh class B\u002FC) or ALT\u002FAST \\>3x upper limit of normal at screening.\n* Active malignancy requiring systemic therapy (except adequately treated non-melanoma skin cancer) within the past 2 years.\n* Known autoimmune disease requiring systemic immunosuppression, or use of chronic systemic corticosteroids above physiologic replacement.\n* Pregnant or breastfeeding, or unwilling to use effective contraception during the study (if of childbearing potential).\n* Known hypersensitivity to peptide therapeutics or study formulation components.\n* Participation in another interventional clinical study or receipt of an investigational product within 30 days (or 5 half-lives, whichever is longer) prior to screening.","ALL","40 Years","75 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This fictional study is an example of a ClinicalTrials.gov-style record. It describes a Phase 1\u002F2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD). Exploratory endpoints assess vascular function and inflammation biomarkers",[29,30],"Atherosclerotic Cardiovascular Diseases","Endothelial Dysfunction",[32,33,34,35,36,37,38,39],"TB-500","thymosin beta 4 fragment","vascular repair","endothelial function","flow-mediated dilation","inflammation","hs-CRP","atherosclerosis","RECRUITING","2026-03-17",{"date":43,"type":44},"2026-03-23","ACTUAL",{"date":46,"type":44},"2026-02-05",{"date":48,"type":22},"2028-02-17",{"name":50,"class":51},"Hudson Biotech","INDUSTRY",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":5},"100618503","digital-remote-management-for-care-and-continuous-optimization-versus-usual-care-to-reduce-risk-of-atherosclerotic-cardiovascular-diseases-digicare-ascvd-100618503","NCT07332468","Digital Remote Management for Care and Continuous Optimization Versus Usual Care to Reduce Risk of Atherosclerotic Cardiovascular Diseases (DigiCare-ASCVD)","DigiCare-ASCVD","Inclusion Criteria:\n\n1. 10-year ASCVD risk ≥ 10%, calculated using the China-PAR risk prediction model\n2. Adultd aged ≥ 35 years\n3. Able to use a smartphone (or assisted by family) and agrees to remote management\n4. Signed informed consent\n\nExclusion Criteria:\n\n1. History of acute myocardial infarction, stroke, heart failure, malignant arrhythmia, or prior percutaneous coronary intervention or coronary artery bypass grafting surgery\n2. Moderate to severe hepatic dysfunction (Child-Pugh class B-C)\n3. CKD stages 4-5 (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m²) or on dialysis\n4. Chronic obstructive pulmonary disease requiring ongoing home oxygen therapy or chronic oral steroid therapy as an outpatient\n5. Pregnant, planning to become pregnant within the next 12 months\n6. Life expectancy \\\u003C12 months (e.g., advanced malignancy, etc.);\n7. Cognitive impairment or communication disorder.","35 Years",{"count":62,"type":22},790,[64],"NA","The DigiCare-ASCVD study is an investigator-initiated, multicenter, open-label, parallel-group randomized controlled trial. It aims to evaluated whether digital remote management is superior to usual care in reducing risk of atherosclerotic cardiovascular diseases and improving blood pressure control, glycemic control, lipids control, medication compliance and lifestyle.",[29],"NOT_YET_RECRUITING","2025-12-31",{"date":70,"type":44},"2026-01-12",{"date":72,"type":22},"2026-01",{"date":74,"type":22},"2027-04",{"name":76,"class":77},"Beijing Anzhen Hospital","OTHER",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100616702","phase-1-phase-1-study-of-the-safety-and-pharmacokinetics-of-yn001-with-rosuvastatin-in-healthy-chinese-subjects-100616702","NCT07309042","Phase 1 Study of the Safety and Pharmacokinetics of YN001 With Rosuvastatin in Healthy Chinese Subjects","A Randomized, Open-label Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of the Combination of YN001 and Oral Rosuvastatin Calcium Tablets in Healthy Chinese Individuals","Inclusion Criteria:\n\n1. Fully understand the purpose, characteristics, research methods and potential adverse reactions of this study, voluntarily participate in the study as a subject, and sign the Informed Consent Form (ICF) before any assessments are performed.\n2. Healthy Chinese male and female subjects aged 18 to 55 years (inclusive, based on the age at the time of signing the ICF).\n3. Body weight ≥ 50 kg for males and ≥ 45 kg for females; body mass index (BMI) ranging from 18 to 28 kg\u002Fm² (including the critical values).\n4. Judged by the investigator based on medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function) and viral serological test results (normal or abnormal without clinical significance) to be in good general health.\n5. Female subjects must be non-pregnant and non-lactating; female subjects of childbearing potential (including female partners of male subjects) must agree to use effective contraceptive methods such as abstinence, condoms, intrauterine devices in use, double barrier methods (e.g., condoms plus diaphragms) from the screening period until 6 months after receiving the last dose of the study drug.\n6. Willing and able to comply with the requirements of the study protocol.\n\nExclusion Criteria:\n\n1. Participation in other clinical trials within 3 months prior to the first dose or within 5 half-lives (whichever is longer). Subjects who withdrew from the study before receiving the study drug (i.e., not administered the drug) are eligible for enrollment.\n2. Use of any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or health supplements within 2 weeks prior to the first dose, or receipt of any type of vaccination.\n3. Consumption of diets that may affect the in vivo metabolism of drugs (including grapefruit or grapefruit products, pitaya, mango, etc.) within 7 days prior to screening, engagement in strenuous exercise, or consumption of other diets that the investigator deems may affect the absorption, distribution, metabolism, or excretion of drugs.\n4. History of severe food allergies (e.g., anaphylactic shock). Mild food allergies such as lactose intolerance and glucose intolerance are not excluded.\n5. Allergy to multiple drugs, history of allergy to rosuvastatin, or history of allergic reactions to any component of the study drugs.\n6. Known presence of clinically significant abnormal diseases or factors, including but not limited to clinically significant abnormalities in abdominal color Doppler ultrasound (liver, gallbladder, spleen, pancreas, bilateral kidneys, ureters, urinary bladder), chest posteroanterior radiography, etc.; or clinically significant diseases (including but not limited to diseases of the digestive system, circulatory system, respiratory system, endocrine system, urinary system, immune system, nervous system, and mental and psychological diseases) shown by other clinical findings within 6 months prior to screening.\n7. History of myopathy\u002Fmyalgia, or predisposition to myopathy\u002Frhabdomyolysis (e.g., family history of hereditary myopathy, previous combined use of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors and fibrates, etc.).\n8. Presence of hypothyroidism or hyperthyroidism.\n9. History of acute or chronic bronchospastic diseases (including asthma, chronic obstructive pulmonary disease, whether treated or not) or heart failure, myocardial infarction, with a history of onset or recurrence within the past 3 years.\n10. Known history of inflammatory bowel disease, ulcers, gastrointestinal bleeding, or rectal bleeding within 6 months prior to the first dose.\n11. History of pancreatic injury or pancreatitis within 6 months prior to dosing.\n12. Presence of symptoms of urinary tract obstruction or dysuria.\n13. History of autonomic nervous system disorders (e.g., recurrent syncope, palpitations, etc.), with a history of onset or recurrence within the past 3 years.\n14. Suffering from a major unhealed disease within 2 weeks prior to the first dose; or expected to undergo major surgery during the study period.\n15. History of renal impairment, manifested by clinically significant abnormalities in creatinine, blood urea nitrogen (BUN) and\u002For urea levels, or clinically significant abnormalities in urine components (e.g., proteinuria).\n16. Presence of liver disease or liver injury, or abnormal liver function test results. Subjects who meet any of the following criteria must be excluded from the study:\n\n    1. Any one of alanine aminotransferase (ALT), aspartate aminotransferase (AST), or serum bilirubin exceeds 1.5 times the upper limit of normal (ULN).\n    2. Any two or more of ALT, AST, or serum bilirubin exceed the upper limit of normal (ULN).\n17. History of clinically significant electrocardiogram (ECG) abnormalities; or presence of any of the following abnormalities during screening or baseline period:\n\n    1. QTcF (males) \\> 470 milliseconds (msec).\n    2. QTcF (females) \\> 480 milliseconds (msec). (Corrected by the Frederica formula, calculated as QTcF = QT\u002F(RR⁰·³³))\n18. Screening test shows hemoglobin level \\\u003C 120 grams per liter (g\u002FL) in males and \\\u003C 110 grams per liter (g\u002FL) in females.\n19. Blood donation or blood loss exceeding 400 milliliters (mL) within 3 months prior to screening.\n20. Smoking more than 10 cigarettes per day or habitual use of nicotine-containing products within 3 months prior to screening.\n21. History of drug abuse within 12 months prior to screening; or use of any illegal drugs within 3 months prior to screening; or positive results in drug abuse tests (e.g., amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, morphine, etc.) during screening.\n22. Weekly alcohol consumption exceeding 14 standard drinking units (1 standard drinking unit = 285 mL of beer, or 25 mL of spirits, or 150 mL of wine) within 3 months prior to screening; or consumption of alcohol-containing products within 48 hours prior to the first dose; or positive results in breath alcohol test during the baseline period.\n23. Positive results in tests for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or Treponema pallidum antibody.\n24. The investigator deems the subject unsuitable for participation in the study due to any other diseases or conditions.",true,"18 Years","55 Years",{"count":89,"type":22},24,[25],"The primary objective of this study is to investigate the safety and tolerability of YN001 in combination with rosuvastatin, so as to provide evidence for the feasibility of YN001 combined with statins in subsequent clinical trials.",[29,93],"Cerebrovascular Diseases","2025-12-15",{"date":96,"type":44},"2025-12-30",{"date":98,"type":22},"2025-12",{"date":100,"type":22},"2026-02",{"name":102,"class":51},"Beijing Inno Medicine Co., Ltd.",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100583068","effectiveness-of-decision-support-for-cardiovascular-risk-management-in-people-with-cardiovascular-disease-100583068","NCT06871514","Effectiveness of Decision Support for Cardiovascular Risk Management in People With Cardiovascular Disease","2-DECIDE: A Stepped-Wedge Multicenter Study on the Effectiveness of a Multicomponent Intervention With Shared Decision-Making to Improve Cardiovascular Risk Management in Adults With Established Atherosclerotic Cardiovascular Disease","2-DECIDE","Inclusion criteria:\n\n* Established ASCVD\n\n  * At least 30 days since last CVD event and\u002For the diagnosis of ASCVD. If no CVD events have occurred, imaging confirming ASCVD must have been conducted at least 30 days prior.\n  * Documented ASCVD (defined according to the 2021 European Society of Cardiology guideline), which includes ASCVD established clinically or demonstrated unequivocally by imaging:\n* Clinically documented ASCVD includes previous myocardial infarction, acute coronary syndrome, coronary revascularization (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Surgery (CABG)), and other arterial revascularization procedures, ischemic stroke or transient ischemic attack, and peripheral artery disease (from Fontaine stage II). Angina pectoris (stable) without imaging evidence of atherosclerosis does not qualify as ASCVD.\n* ASCVD unambiguously identified through imaging, includes significant stenosis (\\>50%) on coronary angiography, computed tomography angiography, or carotic ultrasound. It also includes aortic aneurysms measuring ≥3cm. Only Carotid Intima-Media Thickness measurements (cIMT), Coronary Artery Calcium scoring or abnormal ankle-brachial index scores without evidence of stenosis, do not qualify as ASCVD.\n* Age 40-80 years (to allow for individual risk predictions with the SMART2 model\n* Patient attending the Cardiology or Vascular Medicine outpatient clinic\n* Sufficient understanding of the Dutch language (due to the questionnaires being administered in Dutch).\n* Written informed consent must be provided. Although the proposed intervention is not subject to the WMO, informed consent is required for the collection and processing of data, including the distribution of questionnaires.\n\nExclusion criteria:\n\n* Patients currently participating in other interventional medication studies, or studies that directly affect the therapy plan\n* Remaining life expectancy of less than 2 years as assessed by a consulting healthcare professional (these patients have no indication for cardiovascular risk management)\n* Patients for whom individual risk predictions with the SMART2 model are not feasible:\n\n  * Systolic Blood Pressure (SBP) \\\u003C90 mmHg or \\>200 mmHg\n  * Total cholesterol \\\u003C2.5mmol\u002FL or \\>8 mmol\u002FL\n  * High-Density Lipoprotein (HDL) cholesterol \\\u003C0.6mmol\u002FL or \\>2.5 mmol\u002FL\n  * Low-Density Lipoprotein (LDL) \\\u003C0.1 mmol\u002FL or \\>7.4 mmol \u002FL\n  * Estimated Glomerular Filtration Rate (eGFR) \\\u003C30ml\u002Fmin\u002F1.73m2 or dialysis\n  * Active treatment for malignity, pregnancy, history of organ transplantation, or liver failure\n* Previous participation in 2-DECIDE","80 Years",{"count":113,"type":22},1200,[64],"This study aims to improve the way patients with cardiovascular diseases are informed about their treatment options. It explores methods to support shared decision-making between patients and doctors. In some cases, doctors will take extra time to discuss treatment options in detail. To assess the impact, some patients will be asked to complete questionnaires after their clinic visits.",[29,117],"Shared-decision Making","2025-03-11",{"date":120,"type":44},"2025-03-12",{"date":122,"type":44},"2025-02-18",{"date":124,"type":22},"2028-12-31",{"name":126,"class":77},"dr.Frank L.J. Visseren",8,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":136,"targetDuration":138,"studyType":139,"phases":4,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":52},"100552339","multi-omics-merge-for-ensemble-subtyping-for-atherosclerotic-cardiovascular-disease-100552339","NCT06471803","Multi-omics Merge for Ensemble Subtyping for Atherosclerotic Cardiovascular Disease","Multi-omics Merge for Ensemble Subtyping for Atherosclerotic Cardiovascular Disease and Related Mechanism Study","ASCVD-MOMENT","Inclusion Criteria:\n\n1. aged more than 18 years\n2. meet the diagnostic criteria of coronary heart disease\n3. undergo coronary angiography after admission and have at least 50% stenosis in at least one major coronary artery\n4. able to sign the informed consent form\n\nExclusion Criteria:\n\n1. severe valvular disease (defined as valvular disease stage C or D)\n2. hypertrophic cardiomyopathy; pulmonary heart disease 2) gastrointestinal disease\n3. hyperthyroidism, anemia, or any other high-intensity heart disease\n4. malignant tumors\n5. severe dysfunction of the liver (defined as alanine aminotransferase or total bilirubin greater than 3 times the upper limit of normal) or kidney (defined as eGFR) \\>20 mL\u002Fmin\u002F1.73m2 or requiring dialysis)\n6. severe congenital heart disease\n7. severe infectious or contagious disease\n8. autoimmune disease\n9. age \\\u003C18 years\n10. patients with incomplete clinical records",{"count":137,"type":22},500,"2 Years","OBSERVATIONAL","The current biological issues driving the evolutionary progression of coronary artery disease are in focus: at this stage, the biological evidence for them is scarce and small in scale, with the exception of metabolomics and microbiomics. Issues such as histologic mapping of coronary atherosclerosis deterioration remain to be corroborated by more clinical and basic evidence! By analyzing the clinical data and multi-omics data of patients with coronary heart disease, investigators will explore the related risk factors and establish molecular subtypes and prognostic prediction models for individualized prediction of coronary heart disease risk, in order to guide the clinical screening of high-risk groups of coronary heart disease and formulate more targeted intervention countermeasures.",[29],"2024-06-23",{"date":144,"type":44},"2024-06-25",{"date":146,"type":22},"2024-09-01",{"date":148,"type":22},"2026-03-01",{"name":150,"class":77},"Henan Province Clinical Research Center for Cardiovascular Diseases"]